Radiation therapy has been used to treat animal cancers for more than 100 years. Clinical experiences and experimental results have been widely published and provide a basis for the recognition of radiation therapy as an integral component of multimodal cancer management in veterinary oncology. As the expectations of pet owners and the demand for treatment of companion animals with cancer have increased, veterinary oncology itself has undergone dramatic advances in the past several decades both in terms of improved diagnostics and treatments, including increased accessibility of radiation therapy. Synchronous with development of the specialism of veterinary radiation oncology, confusion and controversy have arisen with regard to distinguishing between different types of radiotherapy and methods of treatment delivery. Importantly, the confusion extends beyond semantics, and includes opinionated debate about defining which forms of therapy (if any at all) are optimal for a given patient. This exemplifies how, despite marks of maturity including age and a robust publication history, the field of veterinary radiation oncology is in some ways still in its infancy. The purpose of this article is to review the evidence base for daily (fine) fractionation versus weekly (coarse) hypofractionation in veterinary oncology, using selected tumour types as examples.
INTRODUCTION
Radiotherapy (RT) has been used to treat veterinary cancer patients for many years. In fact, the first report of radiation therapy in an animal was published in 1905, just 10 years after Wilhelm Roentgen discovered x-rays (Eberlein 1905) . In physician-based medicine, Henri Coutard observed that higher doses of radiation yielded improved tumour control, large doses per fraction led to more damage in late-responding normal tissues, and extending treatment over too long a period would adversely impact tumour control (Coutard 1937) . He is also credited with developing the fractionation schemes that form the basis for conventional irradiation protocols in common practice today: daily 2 Gy fractions (Gy is an abbreviation for Gray, which is the standard unit for therapeutic radiation dose. One Gray is equal to 1 J of ionising radiation absorbed per kilogram of tissue.), given for about 6 weeks. The early history of veterinary radiation oncology is similar. In 1958, Alois Pommer published a comprehensive report of his experiences using orthovoltage radiation to treat animals at the Roentgen Institute in Vienna, Austria; his protocols generally spanned 4 to 5 weeks, and involved delivering 3 fractions per week to a total of 36 to 45 Gy (Pommer 1958) . As access to radiation therapy equipment expanded, the evolution of veterinary radiotherapy protocols diverged along two distinct pathways. In the USA, Mack Emmerson (who trained under Pommer in Europe) installed an orthovoltage unit at the University of Pennsylvania in 1938, and later in the 1950s and 1960s, William Carlson and Edward Gillette oversaw development of the radiotherapy programme at Colorado State University. Both institutions adopted Pommer's protocols, and ultimately switched to daily 2•5 to 3 Gy fractions, to a total of 50+ Gy (hereafter referred to as daily fine fractionation). In the UK, Larry Owen worked with an orthovoltage unit at the Cambridge veterinary school site but also had access to a clinical linear accelerator in the late 1960s. Acute side effects generally result from damage to the stem cell compartments of self-renewing tissues (e.g. colonic crypt cells and basal cells of the dermis and oral mucosa). Therefore, they most commonly occur in rapidly proliferating tissues, and develop during, or shortly after completion of, RT. They can be quite unpleasant, but heal quickly, and are usually self-limiting. (A) An example of oral mucositis developing on the maxilla, towards the end of radiation therapy for an intra-nasal tumour. (B) How radiation dermatitis heals over the weeks following treatment cessation Unlike the equipment that was onsite and dedicated for veterinary use in the USA, Owen's access to a linear accelerator was limited to a unit in a local human hospital, and this led him to use large weekly fractions of radiation (referred to as weekly hypofractionation or coarsely fractionated radiotherapy). All of these protocols were developed before biologists started to understand the underlying mechanisms of how to optimise fractionation. Nonetheless, just as Coutard's protocol remains the basis for RT protocols in today's evolving field of physician-based radiation oncology, so too do the approaches of the 1960s influence and permeate modern practice in veterinary radiation oncology.
The past decade has seen a dramatic increase in the number of veterinary centres offering radiotherapy and, along with advances in imaging modalities and sophisticated computeraided radiation planning systems, this has given rise to debate over the optimum way to deliver radiation, in terms of treatment protocols (Farrelly & McEntee 2014) . The biological effects of radiation are largely governed by time (dose rate, duration of the interfraction interval and overall treatment time), and the amount of radiation applied (total dose and dose per fraction). As a result, fractionation is very important, especially in late-responding tissues, which are more sensitive to increasing fraction size than acutely responding tissues. Of note, radiation side effects occur in locally irradiated tissues, and are classically defined as two distinct syndromes: acute and late (Figs 1 and 2 ). The severity of these radiation toxicoses may be graded according to published criteria (LaDue & Klein 2001) . Furthermore, there are several mathematical models that allow comparison of different fractionation schemes, with regard to risk of toxicity and likelihood of therapeutic efficacy (Fowler 2010) . Therefore, the radiation treatment prescription will depend upon treatment intent.
Curative/definitive-intent protocols aim to maximise efficacy and minimise (late) toxicity. In fact, radiation therapy prescriptions are generally designed to optimise uncomplicated tumour control, meaning that the radiation oncologist prescribes a dose and fractionation schedule which is expected to result in an acceptable risk of dose-limiting toxicity. For many definitiveintent protocols, this is generally regarded as a 5% risk of severe late side effects. By contrast, palliative-intent protocols have traditionally employed larger and less-frequent doses of radiation. Palliative protocols also typically involve a less-sophisticated approach to planning, with a primary goal of retarding tumour growth and alleviating associated pain, and less regard for longterm consequences (i.e. durability of tumour control and late radiation side effects). As with definitive-intent protocols, the goal of palliative-intent radiotherapy is often to treat the tumour and patient to "normal tissue tolerance". However, dose-limiting toxicities shift in the setting of palliative-intent therapy, and the prescribed dose is set to control the tumour as well as possible, while limiting the risk of severe acute toxicities that could degrade short-term quality of life. Notably, there are also situations where A treatment protocol is defined by total dose, number of fractions, dose intensity and the radiation planning and delivery system. The clinical impact of a given treatment protocol is dictated by many additional factors, including tumour biology, stage of disease, co-morbidities, etc. Predictions of clinical impact are used to describe the intent of a given protocol, which is most often categorised as being either palliative, or definitive/curative. This is a challenge because many so-called definitive-intent irradiation protocols (e.g. 54 to 57 Gy in daily 3 Gy fractions for an intranasal carcinoma) are clinically deployed with little hope of a cure. In these cases, it may be useful to discard such binary thinking, and instead consider the many shades of palliation. Likewise, there are diseases that can be cured with low total doses (regardless of fractionation), and other diseases that will progress in the face of the highest imaginable doses of radiation. As such, we urge clinicians to avoid interchangeably using descriptors of protocol (e.g. coarse fractionation) and intent. adequate palliation can be achieved with radiation doses that are below normal tissue tolerance.
As the understanding of the biological mechanisms underlying radiation's efficacy and toxicity improve, and the available radiation delivery technologies expand, there has also been a rapid expansion in the number and variety of different radiation prescriptions, radiation treatment techniques and combinations with other anti-neoplastic therapies. For example, in some circumstances, extreme hypofractionation can be combined with high precision and high accuracy treatment planning and delivery. This approach (stereotactic radiotherapy; SRT) physically shields normal tissues from potentially damaging radiation exposures, and so allows deployment of a much higher dose intensity than has ever before been possible (e.g. daily delivery of very large fractional doses, rather than weekly). The SRT approach seems to offer similarly efficacious alternatives to the daily finely-fractioned approaches that are commonly used for diseases such as canine intranasal and brain tumours. Short-courses of modestly hypofractionated (e.g. 4 Gy in five daily fractions, or 3•5 to 4 Gy in four twice-daily fractions) radiation are also now commonly used in lieu of weekly hypofractionation. Such protocols do not aim to emulate the expected efficacy of a definitive-intent treatment protocol, but to maximise convenience of the treatment schedule, avail the patient of the palliative benefits of treatment as quickly as possible, and limit the risk of severe late radiation side effects (for which incidence increases with increasing fractional dose). However, there is continued (opinionated) debate among veterinary professionals about defining these protocols, and in large part, despite the advances in knowledge, veterinary radiation oncologists can be crudely divided into two camps (that are defined by the original RT protocols): those in favour of daily fine fractionation, and those in favour of weekly hypofractionation as a means for delivering definitive-intent therapy (Box 1).
The veterinary literature contains numerous small scale, often retrospective, studies using widely varying radiation protocols and, as a result, the 'optimum' protocol for a tumour type has yet to be established. This is similar to the human field where the use of different dose/fractionation prescriptions are still to be optimised. The purpose of this article is to systematically review the published literature to provide an evidence base for the relative efficacy of daily fine fractionation versus weekly (coarse) hypofractionation in veterinary oncology, in different clinical scenarios.
DATA SOURCES FOR EXAMPLE PROTOCOLS
PubMed was used to search for published literature on radiation treatment of gross disease using canine intranasal tumours and oral melanomas as examples, and on the use of radiation as an adjuvant to surgery using canine soft tissue sarcoma (STS) as the tumour type. Studies were considered "relevant" if they presented more than 10 cases of the tumour type and provided outcome measures such as survival times and information on toxicity. For nasal tumours, PubMed search terms included ("dog" OR "dogs") AND ("nose" OR "nasal") AND ("tumour" OR "neoplasm*" OR "neoplasia" OR "cancer" OR "carcinoma*" OR "sarcomas") AND ("radiation" OR "radiotherapy" OR "irradiation"). There were 102 search results. Papers were considered irrelevant if they did not report on clinical outcomes of canine nasal tumours (n=10), or if the primary objective was description of tumour biology or radiation physics, without correlation of results to tumour control or survival (n=12). Papers were excluded if they were review papers (n=4), published in a language other than English (n=1), or if there were fewer than 10 cases (n=12). Papers were also excluded if the majority or all of the cases were treated with: re-irradiation only (n=4), radiation modalities other than external beam megavoltage x-rays (e.g. protons, intraoperative RT, orthovoltage x-rays) (n=10), a primary treatment other than RT, or if RT was combined with surgery or hyperthermia (n=14). Finally, papers were excluded if survival outcomes were not reported, or could not be associated with a specific treatment approach (n=14), and two papers were excluded because they reported on tumours of the muzzle or nasal planum, and three papers were excluded due to description of multiple species. One paper reported on clinical outcomes of dogs with solid intranasal tumours that underwent no treatment. Nineteen reports met all inclusion and exclusion criteria. References were scanned for other relevant primary source material, and identified four additional manuscripts that met all inclusion and exclusion criteria (Lana et al. 1997 , Mellanby et al. 2002 , Lawrence et al. 2010 , Fujiwara et al. 2013 .
Unfortunately, it became apparent that the published literature contains too few veterinary radiotherapy studies for oral melanoma (77 publications with eight relevant hits, when PubMed was searched for "Canine Melanoma Radiation") and adjuvant STS (347 search results with six relevant studies when PubMed was searched for "Canine Sarcoma Radiation") to permit a valid systematic review for these scenarios. Abbreviations: fr/wk (fractions per week); SRT (stereotactic radiation therapy); SRS (stereotactic radiosurgery). This plot was compiled from data included in the following references: No treatment (Rassnick et al. 2006 ); 1 to 2 fr/wk; <40 Gy (Mellanby et al. 2002 , Yoon et al. 2008 , Belshaw et al. 2011 , Maruo et al. 2011 , Mason et al. 2013 , Sones et al. 2013 , Fujiwara et al. 2013 ); 3 to 5 fr/wk; 40+ Gy (McEntee et al. 1991 , Theon et al. 1993 , Lana et al. 1997 , Adams et al. 1998 , Lana et al. 2004 , Nadeau et al. 2004 , Yoon et al. 2008 , Adams et al. 2009 , Lawrence et al. 2010 , Hunley et al. 2010 , Sones et al. 2013 ; SRT/SRS (Glasser et al. 2014 , Kubicek et al. 2016 , Gieger & Nolan 2017 Example of radiotherapy as the primary treatment for gross disease: canine intranasal tumours Nasal tumours form a good example of a condition for which radiotherapy is well-established as the treatment of choice yet there is no standard definitive or palliative prescription. Numerous daily, Mon-Wed-Fri, and weekly protocols -and variations on these -have been described. Survival times are highly variable but, generally, most protocols result in an improvement in the associated clinical signs, and increase survival beyond that of dogs managed medically (median 95 days; 95% CI: 73 to 113 days) (Rassnick et al. 2006) . As compared with weekly hypofractionation, full-course RT does seem to improve outcomes for at least some dogs (e.g. those with chondrosarcomas, and those with low-stage tumours). On the other hand, the acute morbidity (e.g. oral mucositis, keratitis and blindness) associated with full-course RT (when planned and delivered using conventional two-and three-dimensional conformal irradiation techniques) may not be acceptable for other cases (e.g. squamous cell carcinoma, or stage IV disease) for which prognosis does not seem to differ much between daily fine fractionation and weekly hypofractionation (Adams et al. 1987 (Adams et al. , 2009 ). Formal comparison of toxicity that has been associated with the various treatment protocols in the published veterinary literature is precluded by inconsistent toxicity scoring and reporting. Furthermore, the studies published on RT for canine nasal tumours differ in the fractionation schedule, dose per fraction and, consequently, the total delivered dose. For the papers that met all inclusion and exclusion criteria for our systematic literature review, reported median survival times ranged from 315 to 580 days for protocols that delivered a total of at least 40 Gy with 3 to 5 weekly fractions. Median survival times ranged from 194 to 512 days for protocols that delivered less than 40 Gy in 1 to 2 weekly fractions. Differences in study design (e.g. methods for calculating survival time) preclude accurate and direct comparison of these various reports, but Fig. 3 summarises the reported survival outcomes. A number of studies have also reported that coarsely fractionated RT can provide good palliation of clinical signs of epistaxis, sneezing and nasal discharge, and permit survival times of between 146 and 512 days (Mellanby et al. 2002 , Yoon et al. 2008 , Fujiwara et al. 2013 . The wide range in reported outcomes from these (numerically small) studies reflects in part the diversity of tumour types which may arise in the sino-nasal cavities, their biological aggressiveness and stage at which they present. However, the complexity of the anatomy of the affected area and, often, proximity of the tumour to critical tissues such as eye and brain, present a huge challenge in RT treatment planning and delivery for tumours at this site. This pertains especially to cases in which the tumour involves the frontal sinus and extends ventrally into the rostral naso-pharynx, effectively encircling the olfactory bulb(s). This factor may also explain some of the differences in outcome and toxicity in different studies. Where available, more advanced radiotherapy techniques can be used to treat canine nasal tumours and allow targeting of tumour and physical shielding of normal tissues (see Fig. 4 ). Initial outcome data for such techniques (e.g. intensitymodulated radiation therapy and proton therapy) are encouraging, and suggest that the survival advantage conferred by more intensive radiation prescriptions can be delivered with limited acute toxicity, thus enhancing oncologic outcomes and patient experiences (Kaser-Hotz et al. 2002 , Vaudaux et al. 2007 , Hunley et al. 2010 , Lawrence et al. 2010 , Glasser et al. 2014 , Kubicek et al. 2016 , Gieger & Nolan 2017 .
While most RT centres would likely advise a finely fractionated RT protocol to maximise prognosis for dogs with nasal tumours, such protocols have not to date been shown to achieve cure for the majority of patients. When factors such as the need for multiple anaesthetics, frequency of visit, severity of acute dermal and oral mucosal toxicity and financial concerns (cost of treatment, travel or board) are taken into account, a hypofractionated option may offer an attractive option for patients with advanced stage disease or significant co-morbidities. SRT is an interesting emerging option that minimises treatment-associated morbidity, maximises convenience and may even maximise efficacy, particularly for dogs with advanced stage disease (Glasser et al. 2014 , Kubicek et al. 2016 , Gieger & Nolan 2017 . Although this option is increasingly accessible to pet owners around the globe, location does remain a limitation. Discussion of doseintense SRT protocols is not directly relevant to the comparison of weekly hypofractionation and daily fine fractionation, but the citations are included here (and in Fig. 3) for completeness, and to allow readers to contextualise the other data with emerging and frequently used treatment approaches. Similarly, data from reports of orthovoltage techniques for treatment of canine intranasal neoplasia are excluded from Fig. 3 ; while this modality is effective, it is also increasingly considered antiquated and rarely used in modern clinical practice.
Example of radiotherapy as an adjuvant to surgery: canine STS Dogs with high-grade STSs have a relatively high risk of developing metastasis but those are a minority and, for most dogs with low-and intermediate-grade STS, local control is the primary goal of treatment. Aggressive surgery has been associated with an approximately 15% risk of local tumour regrowth (Kuntz et al. 1997) . For cases in which aggressive surgery would result in unacceptable morbidity, radiotherapy can be used to improve outcomes. Radiation therapy does not yield durable local tumour control when used as the sole treatment for canine STS (Gillette et al. 1992) , and relatively low total dose orthovoltage protocols applied in the postoperative setting result in recurrence rates of 36 to 60% (Evans 1987 , Graves et al. 1988 ), but there is a clear dose-response relationship for canine STS treated with orthovoltage and megavoltage radiation therapy (Hilmas & Gillette 1976 , McChesney et al. 1989 , suggesting that radiation has a role in the management of STS.
A systematic overview of radiation effects in human sarcoma patients concluded that "there is strong evidence that adjuvant radiotherapy improves the local control rate in combination with conservative surgery in treatment of STS of extremities and trunk in patients with negative, marginal or minimal microscopic positive margins. A local control rate of 90% has been achieved" (Strander et al. 2003) . The same review stated there to be insufficient evidence to establish whether preoperative or postoperative radiotherapy was more favourable for patients presenting with bulky disease, but that preoperative radiotherapy resulted in more wound complications. Therefore, as in humans, in veterinary oncology it is widely believed that marginal excision of a bulky sarcoma can be combined with relatively high total doses of radiation as a curativeintent local treatment, although high-level evidence to support this view is lacking. In an evidence-based review of management of canine STSs, Hohenhaus et al. (2016) graded the veterinary radiotherapy literature as very weak, due to small sample size, retrospective design and lack of comparison group.
The five main studies reported in the literature are summarised in Table 1 . As can be seen, the treatment protocols are highly variable in terms of fraction size, total dose and treatment intervals, but can be broadly divided into those (n=3) delivering "fine" daily or alternate daily fractions to total doses in the region of 50 Gy (42 to 63 Gy) and those (n=2) delivering weekly hypofractionated treatments to total doses of 24 to 36Gy. Bearing in mind the relatively small number of cases in each study, the outcomes are comparable across all these studies, at approximately 80% 1 year and 70+% 2-year disease-free survival rates. There is a trend towards more durable disease-free survival with the higher total dose regimens, but numbers are too small to allow firm or meaningful conclusions to be drawn. One of the main reasons for treatment failure in all of these studies was local tumour recurrence. It is difficult to know whether this reflects biologic behaviour of certain tumours that is not sufficiently predicted by conventional pathologic grading schemes and/or margin evaluation techniques, lack of efficacy of the chosen irradiation protocol, or a failure of treatment planning, the latter being somewhat speculative unless the surgeon has marked the extent of tumour extension at the time of surgery (Box 2). McKnight et al. (2000) reported outcomes of 38 dogs with STSs that were resected to ≤3 cm 3 before radiotherapy and stated that the treatment field extended 2 cm beyond the tumour volume. A total of 16% of dogs (n=8) experienced local recurrence after RT. All recurrences occurred at or beyond the edge of the RT field. Dogs that did not develop local recurrence had The image on the left depicts a standard computerised (three-dimensional conformal) radiation treatment plan, and the image on the right is a highly sophisticated intensity modulated radiation treatment (IMRT) plan. The planned target volume (PTV) is highlighted in magenta. The brain is highlighted in green. Everything lying within the thick cyan line represents tissue being irradiated with 100% of the prescribed dose. The IMRT planned dose conforms well to the PTV, thus demonstrating how modern irradiation techniques have the potential to reduce risks of normal tissue toxicity (in this case, injury to the rostral half of the brain) via physical avoidance a statistically significant improvement in survival. The authors suggested that a higher dose intensity would be tolerable, and would improve the probability of local tumour control. However, given that all local treatment failures occurred outside the RT field, these results also suggest that a margin of greater than 2 cm may improve tumour control (McKnight et al. 2000) . That same year, Forrest et al. published their experience with 35 dogs having received postoperative RT (3 to 4•2 Gy daily, to a total of 42 to 57 Gy) for incompletely excised STSs. Their radiation fields extended 3 cm around the surgical scars and planning was performed with either non-graphic (manual) methods or using a two-dimensional multi-slice RT planning system. Nineteen of the dogs received 57 Gy; the last three fractions were given with a smaller treatment field. Outcomes were not significantly impacted by the total dose of radiation. Eleven (31•4%) dogs experienced local recurrence, at a median time of 1461 days for grade 1 and 2 tumours, and 78 days for the two dogs with grade 3 tumours. This study included some dogs with tumours of the oral cavity which had a statistically significantly lower median survival time (540 days) as compared with other sites (2270 days), but local recurrence rates were no different (Forrest et al. 2000) . In a subsequent publication, Simon et al. (2007) reported outcomes of 39 dogs with incompletely excised STS that were treated with 3 Gy on each of 17 days, plus weekly low-dose doxorubicin (10 mg/m 2 ). Radiation was delivered to a target that extended 3 to 5 cm beyond the tumour, using 250 kVp x-rays. Seven (18%) dogs experienced local tumour recurrence (five occurring within the RT field) with median time to recurrence of 213 days. Tumours with mitotic rates of >9 per 10 high-power fields were more likely to recur, and those dogs survived for shorter periods.
For weekly hypofractionated protocols, Demetriou et al. (2012) reported on 56 dogs with intentionally marginally excised STS (33% low grade, 50% intermediate and 17% high), treated with adjuvant RT delivered to a field that extended 2 to 3 cm beyond the tumour, and 1 cm deep to it. In total, 10 (18%) dogs experienced local recurrence, and 14 (25%) died from tumour-related causes. Three (5%) dogs developed serious, but not life-threatening, complications (wound dehiscence, self-trauma, osteonecrosis). These authors concluded that hypofractionated RT is a viable option that provides good long-term clinical outcomes, with low morbidity. More recently, Kung et al. (2016) reported similar outcomes for 48 dogs with incompletely or narrowly excised STS (30% grade I, 49% grade II and 19% grade III, and one ungraded rhabdomyosarcoma). These dogs were treated with hypofractionated postoperative RT using 6 to 14 MeV electrons, and a minimum of 3-cm lateral margins in all but one case. Local recurrence was observed in 21% of cases (n=10), with 23% developing metastasis. Progression-free survival was 1904 days for dogs with grade I STS, 582 days for grade II tumours and 292 days for dogs with grade III tumours. The authors concluded that local control was attained in a majority of cases, and that because treatment was well-tolerated, this may 
STS Soft tissue sarcoma, Local rec. local recurrence, pulmonary mets pulmonary metastasis, M-to-F daily, Monday to Friday, LinAc Linear Accelerator
Box 2 Proper implementation of adjuvant RT requires consideration and participation from the referring veterinarian from the outset.
Detailed knowledge of the likely tumour bed is prerequisite to careful RT planning. Therefore, acquisition of preoperative tumour measurements and photographs, and placement of radio-opaque markers (e.g. hemoclips or staples) in the surgical bed should be considered a routine and mandatory component of any oncologic surgery that might be followed by RT. Preoperative cross-sectional imaging may also be useful in select cases.
be a reasonable protocol for older patients and when financial limitations exist. The timing of postoperative radiotherapy may be another factor that influences tumour response. Traditionally a delay of 2 to 3 weeks postsurgery is advised to allow for complete wound healing before commencing radiation therapy, as was the case in the McKnight et al. (2000) study. However, in the Demetriou et al. (2012) study delaying RT for more than 4 weeks after surgery was associated with a better outcome. Therapeutic efficacy is influenced by factors that affect radiation responsiveness, including tumour cell oxygen status, tumour growth kinetics and tumourassociated inflammation, all of which may be relevant to residual tumour cells in the postsurgical setting. Surgery itself may increase turnover of residual tumour cells, and the surgical bed environment is characterised by hypoxia, which makes cells intrinsically relatively radioresistant (Gunduz et al. 1979 , McLeod & Thrall 1989 , Zagars & Ballo 2003 . How these factors impact responsiveness to adjuvant radiotherapy in the clinical setting, and whether the benefit of delaying the start of radiotherapy translates to finely fractionated daily radiotherapy protocols, is unknown.
Overall, the goal of combining marginal excision with RT is to deliver a curative-intent treatment. Daily fine fractionation is often recommended as the treatment of choice because higher total radiation doses should yield improved tumour control, while small fractional doses should minimise the risk of serious late radiation-associated complications in animals with an expectation of long-term survival. However, based on the currently available literature, outcomes associated with weekly hypofractionated protocols are not dramatically inferior to those reported for daily fine fractionation and the results reported by Demetriou et al. (2012) and Kung et al. (2016) are encouraging. A formal comparison of risks and benefits of these various protocols would be needed to produce evidence that robustly predicts which individual patients might benefit most from which approach. Such randomised controlled studies would need to include large numbers of subjects and long-term follow-up. In the absence of such data, both daily fine fractionation and weekly hypofractionation can be considered viable treatment options. In determining which approach to use in a clinical setting, careful case selection is important, as some patients are likely to benefit from RT more than others (e.g. consider width of the histologic margin, mitotic rate, grade, tumour histotype and location as factors that likely contribute to risk of local recurrence and expected time to recurrence). Careful planning of RT is also important; for example, 2 to 3 cm margins may be insufficient for some cases and excessive for others. The desired margin size/depth may also dictate radiation quality (e.g. photons versus electrons).
Finally, we acknowledge that the debate about adjuvant radiotherapy protocols must be considered in the light of knowledge that many low grade STSs do not recur even when marginally excised. Published recurrence rates for canine STS following incomplete or close margin resections range from 17 to 28% (Kuntz et al. 1997 , McSporran 2009 . A recent publication based on 350 canine STSs managed in primary care practice, showed that, despite most surgeries being unplanned, the extent of resection was not associated with improved survival or tumour recurrence (Bray et al. 2014) . Local recurrence occurred in 20% cases, and the median survival time was not reached, with 70% proportional survival at 5 years. Thus, despite the limitations described herein, the current evidence base supports the notion that clinical outcomes are likely to be optimised when adjuvant radiotherapy is reserved for cases of low-grade STS for which combined cytoreductive surgery and adjuvant radiotherapy is planned from the outset. Furthermore, acknowledging the limitations of histologic grading, other features (e.g. highly inflamed and/or anaplastic tumours, those which arise in very young patients, and those with rapid growth rates) should also be considered as part of the comprehensive evaluation of a tumour's potential for displaying aggressive biologic behaviour, and when considering the potential pros and cons of intensive locoregional therapy (Perry et al. 2014 , Yap et al. 2017 .
Example of the interface of tumour biology and radiobiology: canine oral melanoma Weekly hypofractionation with moderate total radiation doses may be a very reasonable approach to definitive-intent treatment for tumours that have a low alpha/beta ratio. The alpha/beta ratio is mathematically derived from the shape of radiation doseresponse curves. Acute-responding tissues and many tumours have high alpha/beta values; in these scenarios, dose intensity and total dose are more predictive of outcome than size of the dose fraction. Tissues that are liable to suffer late radiation side effects are characterised by having low alpha/beta values, which indicates that the size of the dose fraction is important, and risk of late toxicity can be reduced by reducing the size of the dose fraction (while maintaining or escalating the total dose of radiation that is administered). Some tumours also have low alpha/ beta values; for these diseases, large fractional doses may improve tumour control. The prototype for a low alpha/beta tumour is human prostate cancer (Vogelius & Bentzen 2013) . Evidence from benchtop experiments suggests that canine transitional cell carcinoma and osteosarcoma might have low alpha/beta ratios (Fitzpatrick et al. 2008 , Parfitt et al. 2011 .
Canine oral melanoma is another example of a tumour whose radio-responsiveness appears characteristic of a tumour with a low alpha/beta value. It has long been established that hypofractionated RT is effective in management of dogs with gross, often inoperable, disease (Theon et al. 1997) , with the complete response rate approaching 70% in one study of 36 dogs (Blackwood & Cancedda et al. (2016) CR complete response, PR partial response, SD static disease, PD progressive disease, MST median survival time, TTP time to tumour progression, PFS progression free survival Dobson 1996) . More recently, another study showed no difference in response between three different protocols (Proulx et al. 2003) . This and further studies documenting radiation response of canine oral melanoma to different fractionation regimes are summarised in Table 2 , which shows broadly comparable response and survival times irrespective of fractionation protocol. However, survival time as an indication of efficacy of local treatment in dogs with oral melanoma may be flawed, because the majority of patients succumb to metastatic disease (with median survival times of around 7 to 10 months) and thus, as indicated by Proulx et al. (2003) , may not survive long enough to benefit from finer fractionation. Based on these observations coarsely fractionated RT seems more rational than daily fine fractionation, as the latter is no more effective, is generally less convenient, and is associated with higher risk of severe acute oral mucositis and pharyngitis.
CONCLUSIONS
In summary, despite the increasing use of radiotherapy in veterinary patients over the past several decades, this review has demonstrated that in many ways, despite marks of maturity including age and a robust publication history, the field of veterinary radiation oncology is in some ways still in its infancy. Although from a radiobiological perspective, the optimal radiation protocols are established, how we translate this into the clinical veterinary setting and take this into account when selecting a treatment protocol for an individual patient remains contentious. It is clear that some strongly held views on "best practice" with respect to radiation protocols lack a clear evidence base, and that it is quite likely that no one protocol fits all tumours or clinical situations, especially in the management of gross disease (as opposed to microscopic or minimal residual disease being treated with adjuvant RT). In addition to oncologic outcomes, other considerations that impact choice of the irradiation protocol include (though are certainly not limited to) co-morbidities, accessibility and cost. There is neither doubt that the application of veterinary radiotherapy is set to increase hugely in the developed world nor that advances in technology relating to imaging and radiation delivery offer potential to greatly improve our ability to deliver a prescribed dose to a defined target while maintaining normal tissues within tolerance. Yet the optimum protocols for a given situation are still largely unknown. For these reasons, it is imperative that the global veterinary radiotherapy community start to work together, to implement large-scale multicentre trials using consistent (enrolment, treatment and follow-up) protocols, and that consider cost-benefit analyses, in order to establish the optimum way(s) of using radiotherapy in companion animals.
